Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Osilodrostat (LCI699) (LCI699) is an effective inhibitor of human 11β-hydroxylase (IC50: 2.5 nM) and aldosterone synthase (IC50: 0.7 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 43.00 | |
2 mg | In stock | $ 61.00 | |
5 mg | In stock | $ 85.00 | |
10 mg | In stock | $ 126.00 | |
25 mg | In stock | $ 207.00 | |
50 mg | In stock | $ 401.00 | |
100 mg | In stock | $ 597.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 74.00 |
Description | Osilodrostat (LCI699) (LCI699) is an effective inhibitor of human 11β-hydroxylase (IC50: 2.5 nM) and aldosterone synthase (IC50: 0.7 nM). |
Targets&IC50 | Aldosterone synthase:0.7 nM, 11β-hydroxylase (human):IC50: 2.5 nM |
In vivo | Osilodrostat and pasireotide monotherapies can significantly affect in the histology and mean weights of the pituitary and adrenal glands, liver, and ovary/oviduct. Osilodrostat is associated with adrenocortical hypertrophy and hepatocellular hypertrophy. The combination of Osilodrostat with pasireotide ameliorates the liver and adrenal gland changes observed with monotherapy and does not exacerbate any target organ changes. Cmax and AUC(0–24h) of Osilodrostat and pasireotide increase in an approximately dose-proportional manner. Osilodrostat treatment reduces urinary free cortisol in patients with Cushing's disease; 78.9% has normal urinary free cortisol at week 22. |
Animal Research | Sixty male and 60 female rats are randomized into single-sex groups to receive daily doses of pasireotide (0.3 mg/kg/day, s.c.), osilodrostat (20 mg/kg/day, p.o.), osilodrostat/pasireotide in combination (low dose, 1.5/0.03 mg/kg/day; mid-dose, 5/0.1 mg/kg/day; or high dose, 20/0.3 mg/kg/day), or vehicle for 13 weeks. |
Synonyms | LCI699 |
Molecular Weight | 227.24 |
Formula | C13H10FN3 |
CAS No. | 928134-65-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (220.03 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Osilodrostat 928134-65-0 Endocrinology/Hormones Metabolism Others Glucocorticoid Receptor Hydroxylase HAC15 cells Cushing syndrome LCI-699 primary human adrenocortical cell cultures inhibit Mineralocorticoid Receptor LCI 699 CYP11B2 CYP11B1 Inhibitor blood pressure LCI699 inhibitor